Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

Further research is welcome, pending which, current preference remains with use of single-agent osimertinib with or without chemotherapy or with combination bispecific antibody and lazertinib TKI ...

Data suggest that taletrectinib “provides clinically meaningful tumor shrinkage and prolonged disease control as a treatment option for advanced ROS1+ NSCLC, regardless of treatment history,” ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...